

TRIAL SCHEDULE 2018-2019

Planned trial issues per financial year	BCR-ABL1 and AML Translocations Identification (BCRTran) - Accredited	Major BCR-ABL1 Quantification (BCRQ) - Accredited	Post-SCT Chimerism Monitoring (Chim) - Accredited	Igh/TCR Clonality Status (Igh) - Accredited	JAK2 p.Val617Phe (V617F) Status (JAK2) - Accredited	FLT3 Mutation Status (FLT3) - Accredited	NPM1 Mutation Status (NPM1) - Accredited	BRAF p.Val600Glu Status for Hairy Cell Leukaemia (BRAF) - Accredited	KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease (KIT) - Accredited	Paediatric Acute Leukaemia Translocations (PALT) - Not Accredited	Pilot Minor BCR-ABL1 Quantification (mBCRQ) - Not Accredited	Pilot BCR-ABL1 Kinase Domain Mutation Status (ABLKDM) - Not Accredited	Pilot Acute Myeloid Leukaemia Gene Panels (AML GP) - Not Accredited
3	3	5	3	3	3	3	3	3	3	3	2	2	2
APRIL 2018	X		X					X					
MAY 2018		X							X				
JUNE 2018					X					X			X
JULY 2018		X				X	X						
AUGUST 2018	X			X					X			X	
SEPTEMBER 2018											X		
OCTOBER 2018		X	X		X					X			
NOVEMBER 2018						X	X						
DECEMBER 2018	X			X									
JANUARY 2019		X	X						X		X		
FEBRUARY 2019					X					X			X
MARCH 2019			X			X	X						

Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.

Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 7604, operating UK NEQAS for Leucocyte Immunophenotyping.